Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Chemotherapy Induced Neutropenia 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 66Paclitaxel 43Radiotherapy 39Carboplatin 29Fluorouracil 27Drug Therapy 20Irinotecan 16toripalimab 15pembrolizumab 15tislelizumab 14camrelizumab 13sintilimab 12Radiotherapy, Intensity-Modulated 11Albumin-Bound Paclitaxel 11S 1 (combination) 10Capecitabine 10130-nm albumin-bound paclitaxel 10apatinib 9Radiation 9Oxaliplatin 9Neoadjuvant Therapy 9Esophagectomy 9Docetaxel 9nimotuzumab 8TP protocol 8Cetuximab 8anlotinib 7Nivolumab 7nedaplatin 6Taxes 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophageal Squamous Cell Carcinoma × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT00069953 2017-02-17

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Radiation Therapy Oncology Group

Phase 2 Completed
43 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡